Direct Answer
Illumina is the dominant supplier of DNA sequencing instruments and consumables globally, holding approximately 80% market share in next-generation sequencing, with a razor-and-blades model where installed instruments drive recurring high-margin reagent revenue across research, clinical oncology, reproductive health, and genomics applications.
Illumina (ILMN): DNA Sequencing and Genomics Infrastructure
Company Snapshot
| Ticker | ILMN |
|---|---|
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Life Sciences Tools and Services |
| Headquarters | San Diego, California |
| Founded | 1998 |
| CEO | Jacob Thaysen |
| Revenue (FY2024) | ~$4.4 billion |
| CIK | 0001110803 |
| Index membership | S&P 500 |
What Does Illumina Do?
Illumina develops and markets integrated systems for the large-scale analysis of genetic variation and biological function. Its primary products are next-generation DNA sequencing (NGS) instruments and the proprietary consumables (reagents, flow cells, library preparation kits) those instruments require. Illumina's sequencing-by-synthesis chemistry underpins the majority of the world's genomic research and is increasingly used in clinical diagnostics.
Founded in 1998 and headquartered in San Diego, Illumina transformed genomics research through a series of technological improvements that drove per-genome sequencing costs from over $1 million in 2007 to under $200 today. This cost collapse, driven almost entirely by Illumina's platform improvements, democratized genomics by making large-scale sequencing feasible for thousands of research institutions and clinical laboratories worldwide.
The installed base of Illumina instruments worldwide runs in the tens of thousands, spanning academic research labs, pharmaceutical companies, clinical genomics laboratories, national health systems, and biotech startups. Each instrument generates years of consumable demand, creating a large recurring revenue stream.
Product Portfolio
Illumina offers sequencing platforms across multiple throughput tiers. The iSeq 100 and MiniSeq serve small labs with lower-volume needs. The MiSeq handles targeted sequencing and smaller genomes. The NextSeq 1000/2000 series targets mid-size labs doing exome and genome sequencing. The NovaSeq X and NovaSeq X Plus are ultra-high-throughput platforms designed for large-scale whole-genome sequencing at high volumes, with the NovaSeq X capable of sequencing thousands of human genomes per year.
Beyond sequencing instruments, Illumina sells microarray products (arrays for genotyping applications), library preparation kits that prepare DNA samples for sequencing, and bioinformatics software through BaseSpace, its cloud genomics platform.
Key Applications
Research applications include whole-genome sequencing for large population genomics studies (UK Biobank, All of Us, genomic medicine initiatives), transcriptomics (RNA-seq to measure gene expression), epigenomics, and metagenomics for microbiome research.
Clinical applications have grown significantly and include: oncology (tumor profiling for precision oncology treatment decisions, monitoring circulating tumor DNA in liquid biopsies), reproductive health (non-invasive prenatal testing for chromosomal abnormalities), rare disease diagnosis, and pharmacogenomics (predicting drug response from genetic variants).
Frequently Asked Questions
How does Illumina make money?
Illumina earns revenue primarily through two streams: instrument sales (sequencing machines ranging from the benchtop MiSeq to high-throughput NovaSeq X platforms, representing roughly 15-20% of total revenue) and consumable sales (flow cells, reagent kits, and library preparation supplies that are required for every sequencing run, representing roughly 70-75% of revenue). The consumable model is structurally attractive because each installed instrument generates recurring reagent demand for its operational life. Service and other revenue (roughly 5-10%) comes from support contracts and software.
What is next-generation sequencing and why does it matter?
Next-generation sequencing (NGS) is a technology that reads the sequence of DNA (or RNA) at high speed and low cost compared to earlier Sanger sequencing methods. Illumina's sequencing-by-synthesis chemistry can sequence an entire human genome for under $200 today (compared to $3 billion for the first human genome in 2001). NGS applications include: oncology (tumor mutation profiling to guide cancer treatment), reproductive health (non-invasive prenatal testing), rare disease diagnosis, infectious disease surveillance, drug discovery, and agricultural genomics. Illumina holds an estimated 80%+ market share in the global NGS market through a combination of instrument performance, reagent ecosystem, and bioinformatics integration.
What was the GRAIL acquisition controversy?
GRAIL is a liquid biopsy company developing blood tests to detect early-stage cancers (Galleri multi-cancer early detection test). Illumina acquired GRAIL for approximately $8 billion in 2021, a company it had originally spun out in 2016. The acquisition faced opposition from the US Federal Trade Commission and European Commission regulators who alleged it would harm competition in the liquid biopsy market by giving Illumina (which supplies sequencing to GRAIL's competitors) a financial incentive to disadvantage rivals. The EU ordered a divestiture in 2023. After years of legal battles and a board proxy fight led by activist investor Carl Icahn, Illumina divested GRAIL as a separately traded company in 2024, resolving the regulatory dispute and allowing management to refocus on the core sequencing business.
What competitive threats does Illumina face?
Illumina faces competition from multiple fronts. Pacific Biosciences (PacBio) and Oxford Nanopore Technologies offer long-read sequencing technologies that can read longer DNA fragments, which is valuable for certain applications (structural variant detection, methylation analysis) where Illumina's short-read technology is less effective. Element Biosciences and Singular Genomics have entered the short-read NGS market with lower-cost platforms. BGI/MGI, a Chinese genomics company, offers competitive sequencing systems and has been expanding outside China. While Illumina retains dominant market share, the competitive landscape has intensified, and the company faces pricing pressure as the per-genome cost falls further.
What are the main risks for Illumina investors?
Key risks include: competitive erosion from long-read sequencing (PacBio, Oxford Nanopore) and new short-read entrants; slower-than-expected NGS clinical adoption limiting the addressable market growth; pricing pressure as sequencing costs continue to decline (the cost-per-genome treadmill that drives volume growth also compresses per-unit revenue); geographic risk from BGI/MGI and potential US-China trade policy impacts on the genomics supply chain; and execution risk following the GRAIL distraction, including potential management turnover and refocusing challenges. Illumina's high historical valuation made it sensitive to growth disappointments.